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Abstract Photodynamic therapy (PDT) induces damage
to the endothelium, which can lead to increased vascular
permeability and, under intensive PDT conditions, even to
platelet aggregation, vasoconstriction, and blood flow sta-
sis. Eventually, ischemia, hypoxia, and inflammation can
occur, resulting in angiogenesis. We studied the sequence of
the vascular events after Visudyne-PDT in the chicken
chorioallantoic membrane (CAM) at day 11 of develop-
ment. Using epi-fluorescence microscopy, we monitored
the regrowth of capillaries in the PDT treated area. Imme-
diately after irradiation, the treatment resulted in blood flow
arrest. And 24 h post PDT, sprouting of new blood vessels
was observed at the edge of the PDT zone. Neovessels
looping out from the edge of the PDT zone gave rise to
specialized endothelial tip structures guiding the vessels
towards the center of the treated area. At 48 h almost all of
the treated area was repopulated with functional but mor-
phologically altered vasculature. These observations also
showed reperfusion of some of the vessels that had been
closed by the PDT treatment. CAM samples were immu-
nohistochemically stained for Ki-67 showing proliferation
of endothelial cells in the PDT area. Also, several markers
of immature and angiogenic blood vessels, such as aVb3-
integrin, vimentin and galectin-1, were found to be
enhanced in the PDT area, while the endothelial maturation
marker intercellular adhesion molecule (ICAM)-1 was
found to be suppressed. These results demonstrate that the
new vascular bed is formed by both neo-angiogenesis and
reperfusion of existing vessels. Both the quantitative real-
time RT–PCR profile and the response to pharmacological
treatment with Avastin, an inhibitor of angiogenesis,
suggest that angiogenesis occurs after PDT. The observed
molecular profiling results and the kinetics of gene regula-
tion may enable optimizing combination therapies involv-
ing PDT for treatment of cancer and other diseases.
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Introduction
Photodynamic therapy (PDT) is a minimally invasive treat-
ment modality that can potentially destroy unwanted neo-
plastic tissue [1] while sparing neighbouring normal tissue.
PDT involves site-specific activation of an administered
photosensitizer using light of an appropriate wavelength, in
order to generate cytotoxic reactive oxygen species that
induce cellular and/or vascular damage, as well as inflam-
matory and angiogenic responses [2–4]. In the vasculature
PDT can lead to cytoskeleton damage in the endothelium and
endothelial cell retraction causing increased space between
these cells. This can lead, when applied in patients, to
exposure of the vascular basement membrane and the release
of Von Willebrand factor, and, as a consequence to platelet
activation and aggregation [2]. The effects of PDT in blood
vessels, such as vessel constriction and stasis of flow shortly
after phototherapy have been described by Star et al. [5].
They speculated that vascular damage plays an important
role in tumor cure next to the direct effects of PDT on tumor
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cells. These findings are supported by the report of Hen-
derson et al. [6] who quantified tumor cell clonogenicity at
various times after PDT and found that the viability of tumor
cells was nearly unaffected by PDT. Also, Selman et al. [7]
demonstrated reductions in blood flow after phototherapy
using a radioactive microsphere method. Reed et al. [8]
studied vessel constriction using an intravital microscopy
model and reported similar results. These studies identified
platelet aggregation and vessel constriction as early events in
PDT.
The angio-occlusive effect of PDT is currently used to
treat non-cancerous vascular diseases. Prominent in this
regard is the worldwide approval (in over 70 countries,
including the USA) of verteporfin (Visudyne)-based PDT
for the treatment of exudative age-related macular degen-
eration (AMD), as well as for subfoveal choroidal neo-
vascularization (CNV) due to pathologic myopia and
ocular histoplasmosis syndrome [9]. A wide range of other
diseases is under investigation for treatment with PDT
using verteporfin or other PDT agents, including rheuma-
toid arthritis [10] and different forms of cancer [11, 12].
A suitable model for studying vascular effects of PDT is
the well-vascularized chorioallantoic membrane (CAM) of
the chicken embryo (Gallus gallus). This model has several
advantages over other animal models, including the fact
that the CAM consists of a thin, planar vascular network,
which is well adapted to observation by microscopy [13].
Furthermore, the CAM provides an easily accessible neo-
vascular network in a transparent matrix. It allows direct
visualization of blood vessels before, during and after PDT,
and during pharmacological intervention. The CAM has
been successfully used to evaluate the photodynamically-
induced vascular occlusion efficacy of some PDT photo-
sensitizers, that are in clinical trials or are already FDA
approved [14–17]. The CAM model has also been exten-
sively used in angiogenesis research [18–20].
Research on the effect of PDT on the vasculature
demonstrated that this treatment often results in the
induction of angiogenesis, which is the major rationale for
combining PDT with anti-angiogenesis therapy. The rela-
tionship between PDT and angiogenesis was first described
by Ferrario et al. [21], who demonstrated that the effec-
tiveness of PDT may be enhanced by combination with
angiogenesis inhibitors, an approach that we also recently
validated [14, 22]. In general, it was assumed that the PDT
induced changes in the tissue result in the formation of new
vasculature. This assumption was mainly based on the
observation of the changed and tortuous appearance of the
vasculature [14, 23, 24], but proof of neovasculature for-
mation by sprouting angiogenesis and vascular prolifera-
tion was not yet provided. Therefore, the present study was
undertaken to investigate in the CAM some of the details of
the mechanism of tissue revascularization after PDT. We
show that neoangiogenesis occurs by observation of vessel
morphology, by immunohistochemical detection of endo-
thelial proliferation markers, and markers of angiogenesis
(galectin-1 and vimentin), as well as by molecular profiling
using real-time RT–PCR. We also suggest that next to new
vessel formation, reperfusion of occluded blood vessels
occurs. Understanding of the mechanisms of PDT-induced
angiogenesis will help to optimize the improvement of
PDT by combination with angiogenesis inhibitors.
Materials and methods
The in ovo CAM model
Fertilized chicken eggs (Animalco AG, Staufen, Switzer-
land) were labelled and transferred into a hatching incu-
bator with a relative air humidity of 65% and a temperature
of 37C. This incubator was equipped with an automatic
rotator (Savimat, Chauffry, France). On EDD 3, a hole of
approximately 3 mm in diameter was opened in the egg-
shell and covered with a Laboratory Wrapping Film,
Parafilm (Pechiney, Menasha, USA) to prevent dehydra-
tation and possible infections. The eggs were then returned
to the incubator in a static position until use. On embryo
developmental day (EDD) 11, the hole in the shell above
the air pouch of the egg is extended to a diameter of
approximately 3 cm in order to provide better access to the
chorioallantoic membrane for the experiments.
For the topical application of compounds, polyethylene
rings were deposited on the CAM. These polyethylene
rings (diameter 5 mm; wall thickness 0.5 mm, 1 mm
height) confine the topical drug to only the small part of the
CAM surface inside the ring. Eggs were placed under an
epi-fluorescence microscope described below and PDT was
performed. After the treatment the eggs were numbered,
covered and returned to the incubator.
Microscopy and image acquisition
Microscopic observation of CAM vasculature and the light
irradiation for PDT were performed with an epi-fluores-
cence Eclipse 600 FN microscope, as described previously
[17, 25], equipped with a Plan Apo 4/0.2, working distance
20 objective (Nikon, Japan). Illumination was provided by
a 100 W high pressure Hg-arc lamp. Light doses were
adjusted with neutral density filters and measured with a
calibrated Field-Master GS power meter (Coherent, Santa
Clara, USA). For exciting and detecting Visudyne, the
microscope was equipped with a BV-2A filter set (kex =
420 ± 20 nm, kem [ 470 nm, Nikon, Japan). For detecting
FITC, light was filtered for excitation at 470 ± 20 nm and
a long-pass emission filter was used for detection of the
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fluorescence (k[ 520 nm, Nikon, Japan). Fluorescence
images were acquired with an F-view II 12-bit mono-
chrome Peltier-cooled digital CCD camera driven with
analySIS DOCU software from Soft Imaging System
(Muenster, Germany).
Visudyne-Photodynamic therapy
This part of the study aimed at performing PDT to observe
the evolution of the vascular network, especially in terms
of vascular occlusion, during the 2 days following treat-
ment. For this purpose, on EDD 11, the egg opening was
extended to 3 cm in diameter, and a volume of 10 ll of
Visudyne (the liposomal formulation of verteporfin [26],
Novartis Pharma, Inc., Hettlingen, Switzerland) was
intravenously administered through a 33-gauge needle fit-
ted to a 100 ll syringe (Hamilton, Reno, USA) into the
main vessel of the CAM. This corresponds to 0.20 mg
verteporfin per kg embryo weight. One minute after
injection, the site with vessels of diameter between 5 and
about 70 lm was irradiated with a light dose of 20 J/cm2
(kex = 420 nm, kem [ 470 nm) with irradiance of 60 mW/
cm2. The irradiation area was 0.02 cm2 as delimited by an
optical diaphragm, within the area inside the polyethylene
ring, which defined the area of possible topical drug
administration. The site was photographed at the beginning
and at the end of irradiation. Subsequently, the egg opening
was sealed with parafilm and the embryo was further
incubated for 24 h before assessing the PDT-induced
damage. The conditions used here in the CAM model are
the same as those that were previously selected in other
studies [14]. They lead to similar angio-occlusion effi-
ciency as observed after Visudyne-PDT in the human eye
at the most prevalent clinical conditions.
Optimal PDT-induced closure of vasculature in the
CAM is defined as closing the same diameter as the cho-
roidal neovessels (CNV) that are targeted in PDT in the
case of wet age-related macular degeneration (i.e. \ 70 lm
in diameter), while leaving the larger vessels open.
‘‘Standard’’ clinical PDT of CNV conditions are a verte-
porfin dose of 6 mg/m2 of body surface (0.15 mg/kg) and
irradiation with 50 J/cm2 at 689 nm, using an irradiance of
600 mW/cm2, 15 min after the start of the slow 10-min
infusion of the drug [27]. The transparency of the CAM
allows using blue light (excitation at 420 nm) in order to
excite the benzoporphyrin. In order to verify the efficacy of
the blood flow stasis and the vascular occlusion induced by
PDT under these conditions, observation of the vasculature
was undertaken daily for the 2 days following the illumi-
nation by means of fluorescence angiographies. These were
performed after i.v. injection of 20 ll of a solution con-
taining of FITC-dextran (20 kDa, 25 mg/ml), followed by
fluorescence angiography using light from an Hg-arc lamp
filtered for excitation at 470 ± 20 nm and with a long-pass
emission filter (k[ 520 nm) for observing the fluores-
cence. In order to increase the quality of the recorded an-
giographs, a light absorber, in the form of India ink, was
injected (30 ll) into the extra-embryonic cavity just under
the deposited polyethylene ring. The purpose of this second
injection was to decrease the influence of the CAM auto-
fluorescence background, which changes rapidly with time
due to the embryo’s movement. The India ink was filtered
using a sterile cellulose acetate membrane (0.2 lm pores,
Renner GMBH, Darmstadt, Germany) just before injection.
Between the treatment and this measurement, the eggs
were again re-covered with parafilm, maintained in the
dark and returned to the incubator.
In order to perform quantitative real-time RT–PCR
experiments on the PDT effect, Visudyne-PDT was per-
formed on a large area of the CAM (0.5 cm2) at EDD 11.
To that end, an Oxxius laser (Oxxius S.A., Lannion,
France) was used, coupled to the frontal light distributor
fiber, SN FD1-1351 (Medlight S.A., Ecublens, Switzer-
land) with an excitation wavelength of 405 nm (applied
light dose of 20 J/cm2 and the irradiance of 25 mW/cm2).
After PDT, embryos were numbered, covered with parafilm
and returned to the incubator. 48 h after PDT (EDD 13) the
treated CAMs were fixed overnight in Zn-fixative solution,
dried and frozen until the RNA extraction procedure.
Combining of Visudyne-PDT with Avastin
This part of the study was designed to observe the pro-
longed vascular occlusion, due to combination therapy
consisting of photodynamic therapy followed by anti-
angiogenesis. Experiments of Visudyne-PDT were con-
ducted as described above. Subsequently, 24 h post
PDT, treated CAMs were i.v. injected with 20 ll of a
solution containing FITC-dextran (20 kDa, 25 mg/ml), and
observed by fluorescence angiography using light from an
Hg-arc lamp filtered for excitation at 470 ± 20 nm and
with a long-pass emission filter (k[ 520 nm). After that,
Avastin (bevacizumab), a product of Genentech, San
Francisco, USA, was administered topically (20 ll, 1.7 mg/
ml; 34 lg/embryo) in the polyethylene ring onto the CAM
surface. In order to observe vascular regrowth after PDT
under these conditions, observation of the vasculature was
undertaken also 48 h post PDT by means of FITC-dextran
fluorescence angiographies (as described above).
Immunohistochemistry
CAMs were fixed overnight in Zn-fixative [28] and
embedded in paraffin. 4 lm sections were cut, dewaxed,
and dehydrated. Endogenous peroxidase activity was
blocked with 0.3% hydrogen peroxide in methanol for
Angiogenesis (2010) 13:281–292 283
123
30 min. Next, antigen retrieval was performed with a
mixture of 2 M HCl and 0.2% Triton X-100 in tris buffered
saline (TBS) for 30 min at room temperature, except for
detection of smooth muscle actin (SMA). Slides were
blocked with 10% normal goat serum and 1% BSA in PBS
for 15 min, and subsequently incubated overnight with
primary antibodies against Ki-67 (clone MIB-1, Dako,
Glostrup, Denmark), aVb3-integrin (clone LM609,
Chemicon/Millipore, Amsterdam, The Netherlands),
galectin-1 (rabbit polyclonal antibody, Peprotech, London,
United Kingdom), vimentin (clone V9, Dako, Glostrup,
Denmark), smooth muscle actin (SMA, clone 1A4, Dako,
Glostrup, Denmark), and ICAM-1 (clone 166623, R&D
Systems Europe Ltd., Abingdon, United Kingdom). Slides
were washed three times with TBS between the antibody
incubations. Visualisation was performed with either
Power Vision poly-HRP kit (Immunologic, Duiven, The
Netherlands) or EnVision ? System-HRP kit (Dako,
Glostrup, Denmark, only for smooth muscle actin and
vimentin). This was followed by the development of the
staining with 3,30-Diaminobenzidine (DAB, Sigma Chem-
icals, The Netherlands) chromogenic substrate. Subse-
quently the slides were counterstained with haematoxylin,
dehydrated and mounted in DePex mounting medium.
RNA isolation and cDNA synthesis
Total RNA was isolated from CAM sections using the
RNeasy RNA isolation kit (Qiagen, Venlo, The Nether-
lands) according to the supplier’s protocol. Prior to column
loading, samples were carefully homogenized in RLT
buffer (Qiagen, Venlo, The Netherlands). Possible genomic
DNA contaminations were removed by on column DNAse
treatment with the RNase-free DNAse set (Qiagen, Venlo,
The Netherlands). RNA quality and quantity were checked
by spectrophotometry (NanoDrop, Thermo Scientific), and
1,000 ng RNA was used as input for first-strand cDNA
synthesis using an iScript cDNA synthesis kit (Bio-Rad
Laboratories, The Netherlands) according to the manufac-
turers’ instructions. Reactions were diluted to 50 ll and
stored at -20C until use.
Primer design
Primers (Fig. 7) were targeted against beta-actin (Actin-b),
cyclophilin-A (Cyclo-A), vascular endothelial growth fac-
tor A (VEGF-A), vascular endothelial growth factor
receptors 1 and 2, (VEGFR-1, -R-2), neuropilin-2 (NRP-2),
basic fibroblast growth factor (bFGF), integrin b3 (ITG-
B3), galectin 1 (GAL-1) and vimentin (VIM). The primers
were specific for chicken (Gallus gallus) sequences and
selected based on the following requirements: (1) primer
melting temperature of approximately 60C, (2) GC
content of approximately 55%, (3) preferably no G at the 50
end, (4) avoid runs of more than three identical nucleotides,
and (5) amplicon length of approximately 100 nucleotides.
Specificity and cross-reactivity were checked with the
Basic Local Alignment Search Tool (BLAST; http://
www.ncbi.nlm.nih.gov/BLAST). All primers were synthe-
sized by Sigma-Genosys, The Netherlands.
Quantitative real-time RT–PCR
Quantitative real-time RT–PCR (qRT–PCR) was per-
formed in 25 ll reactions, containing 19 iQ SYBR Green
supermix (Bio-Rad Laboratories, The Netherlands), 200
nM forward and reverse primer (Fig. 7c) and 1.5 ll cDNA.
Reactions were run on a CFX96 thermal cycler (Bio-Rad
Laboratories, The Netherlands), and consisted of an initial
denaturation for 10 min at 95C followed by 50 cycles of
15 s at 95C and 1 min at 60C. Following each run,
melting curves were generated to verify specific product
formation. Data were analysed using CFX Manager soft-
ware (Bio-Rad Laboratories, The Netherlands) and the
expression of each target gene was quantified relative to the
expression of the reference genes (Actin-b and Cyclo-A)
[29].
Results
Morphological characterization
The aim of this study was to investigate in detail some of
the vascular events after Visudyne-PDT. To that end, we
performed PDT at the stage in which the CAM is already
fully developed—EDD 11—and contains a vessel network
with a regular capillary plexus (see Figs. 1a and 2a) [30].
We used previously optimized PDT protocols, which
caused an almost total occlusion of the treated vessels [14].
Visudyne-PDT caused thromboembolic events, and vas-
cular constriction leading to obstruction of both large
vessels and the capillary bed, which resulted in a complete
perfusion arrest (see Fig. 1b and e). To evaluate the
induction, and maintenance, of vascular occlusion after
PDT, as well as to study the neovascularization and
reperfusion processes, the treated area of the CAM was
observed for 2 days post PDT. 48 h after Visudyne-PDT
a full revascularization had occurred (see Fig. 1c and f).
As has been previously described [14, 23], PDT causes
the induction of inflammation and angiogenesis processes
leading to development of a new functional vascular bed.
After 24 h we observed that revascularization of the trea-
ted area starts by sprouting angiogenesis from existing
vessel arches outside the treatment zone (see Fig. 2c and d,
zone 1), into the angiogenic area. Cellular protrusions of
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the leading edge tip cells can be seen (see Fig. 2b arrow
I-III, and c arrow I). It is also observed that larger vessels
(diameter 30–100 lm) that have been occluded by the
PDT-induced thrombotic events get reperfused (see Fig. 2b
and c, arrow IV), while newly developing small vessels
(Fig. 2d, zone 2, arrow V) replace the original capillary
plexus (like in zone 3).
After 48 h the area is repopulated with functional newly
grown and reperfused vessels. This new vascular bed does
not resemble the morphology of the original capillary
plexus (see Fig. 2c and d, zone 3, in particular for vessels
with diameter 3–5 lm), but instead, consists of larger
vessels (see Figs. 2d, zone 2, and 1f, typically vessel
diameter 5–30 lm) with a more tortuous morphology.
Besides a different morphology, blood flow in these newly
formed vessels is slow and inefficient, sometimes leading
to halted or even reversed flow.
Histological characterization
In order to further investigate the fate and features of the
vasculature after Visudyne-PDT, histology was per-
formed on Zn-fixed and paraffin embedded CAMs. Fig. 3a
shows the gross histological appearance of the CAM 48 h
after PDT over an area of 6.2 mm2. This section is stained
for smooth muscle actin to show the mature vasculature. As
can be seen, the treatment induces wounding of the CAM
tissue (the area between the indicated arrows, Fig. 3a)
leading to a thinner membrane as compared to the
untreated area. In panel B an equivalent part of the CAM is
shown as an angiography, showing the differences in the
vasculature between normal and PDT treated areas
(Fig. 3b).
Immunohistochemical staining of the Ki-67 prolifera-
tion marker was performed, as well as detection of aVb3-
integrin as a marker of immature and angiogenic blood
vessels. Ki-67 was found to be expressed in the vascula-
ture, 48 h after PDT in the exposed area of the CAM
(Fig. 4a). This result implies that new vasculature is
formed by sprouting angiogenesis, requiring proliferation
of endothelial cells. Moreover, we found expression of
aVb3-integrin in the vessels of the PDT treated CAM after
48 h, but not in the non-treated control areas (see Fig. 4b
and c).
The previously identified markers of angiogenic blood
vessels, vimentin [31] and galectin-1 [32], were detected in
the CAM. Our data suggest that these markers are over-
expressed in the newly formed vasculature in the PDT area
as compared to the untreated area (Fig. 5). In addition, a
molecule that is described as being suppressed in angio-
genic endothelium [33] and serves more as a differentiation
marker, i.e. ICAM-1, was found at lower levels of
expression in the PDT area, as compared to the untreated
CAM (Fig. 5). These data together demonstrate that the
Fig. 1 Angiography images of the chorioallantoic membrane (CAM)
vasculature before and after PDT. Images of the CAM before PDT
(a and d) are visualized by Visudyne fluorescence angiography
(0.20 mg/kg embryo weight, kex = 420 nm, kem [ 470 nm). PDT
was performed at a light dose of 20 J/cm2 and an irradiance of 60
mW/cm2; drug-light interval: 1 min). Pictures b and c (objective 49),
and e and f (the same treated area, objective 109) are visualized by
FITC-dextran fluorescence angiography (25 mg/kg, 20 kDa,
kex = 470 nm, kem = 520 nm). Images b and e were taken 24 h
after PDT and show full angio-occlusion in the PDT area. Images
c and f were taken 48 h after PDT, showing the vascular regrowth.
CAM area in pictures a–c is 3.5 9 2.8 mm (objective 49), in d–f is
1.4 9 1.12 mm (1,280 9 1,024 pixels with 4,095 grey levels,
objective 109). In order to increase the contrast India ink was
injected (30 ll) into the extra-embryonic cavity right under the
treated area
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vasculature contains angiogenically-activated blood ves-
sels, and suggests that the formation of neovasculature
occurs after application of PDT.
Evidence for a prominent role of the formation of new
blood vessels in the CAM after PDT was further obtained
by use of the well-known and clinically used angiogenesis
inhibitor Avastin. Although this anti-VEGF antibody was
designed to bind human VEGF, a significant activity
against chicken VEGF has also been reported [14]. Com-
bination treatment of the CAM starting with Avastin 24 h
after PDT hours results in a considerable inhibition of the
regrowth of the vasculature 48 h post PDT (Fig. 6d), as
compared to the observations without Avastin (Fig. 6b).
This is in agreement with our previous findings [14].
Transcriptional expression of angiogenesis genes
To investigate and prove the induction and regulation of
angiogenesis genes after PDT, we determined mRNA
expression of a set of angiogenesis related genes, such as
for VEGF-A, bFGF, VEGF receptors VEGFR-1 and -2,
neuropillin-2, and endothelial angiogenesis markers, such
as integrin b3, vimentin and galectin-1. RNA was isolated
from control CAMs (EDD 11 and EDD 12), as well as from
CAMs extracted 6 h (EDD 11), 24 h (EDD 12), or 48 h
(EDD 13) after application of PDT. Expression of the
tested genes did not differ significantly in the control
groups (EDD 11 and EDD 12). These results were there-
fore all incorporated into a single control group. Fig. 7a–h
show the relative transcriptional expression of the angio-
genesis genes versus the reference genes beta-actin (Actin-
ß) and Cyclophilin-A (Cyclo-A).
VEGF-A was observed to be significantly upregulated by
approximately 2-fold immediately after PDT (6 h, Fig. 7a).
Interestingly, this expression was normalized to control
levels after 24 and stayed unchanged at 48 h. For bFGF a
similar expression profile was found (Fig. 7b), indicating
that angiogenesis is induced by a rapid spiking of activators,
but that this signal is transient. A slower regulation is found
for the VEGF receptors. VEGFR-1 and VEGFR-2 are both
significantly induced by PDT as well. While their expres-
sion was found to be increased by factor of 13.5 (VEGFR-1)
respectively a factor of 3 (VEGFR-2) at 24 h after PDT, the
increase of this angiogenic environment remained at least
Fig. 2 Angiography images of the CAM after PDT visualized by
FITC-dextran fluorescence angiography. a Normal (untreated) small
vessels and capillary network, taken at EDD 13. b and c 24 h post
PDT (EDD 12), whereas d was taken 40 h post PDT (EDD 12/13).
Zones marked below pictures c and d represent: (1) non-regrown
zone, (2) post PDT-regrown zone and (3) non-treated zone on the
CAM. Phenomena of the regrowth process: (I) sprouting originating
from the loop of pre-existing vessels, (II) dead-ended sprout, (III)
filopodia with tip cell, (IV) recanalization of pre-existing, lumen-
reduced vessels within PDT-treated area, (V) ongoing pillar building
in neovascular meshes. In order to increase the contrast India ink was
injected (30 ll) into the extra-embryonic cavity right under the treated
area. Image size: 1.4 9 1.12 mm (1,280 9 1,024 pixels with 4,095
grey levels)
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until 48 h (Fig. 7c and d, respectively). Interestingly, the
expression of another VEGF receptor, neuropillin-2 was
already significantly upregulated 6 h after PDT, and peaked
after 24 h. This receptor upregulation appears to be tran-
sient as well (Fig. 7e). We also tried to measure neuropillin-
1, however this receptor was found not to be expressed at
detectable levels.
The overexpression of integrin-b3 as well as of galectin-
1 and vimentin as found by immunohistochemistry was
confirmed by PCR analysis (Fig. 7f–h).
Discussion
The current work aimed at studying angiogenesis and
neovasculature formation taking place after PDT, as well as
the reperfulsion of vessels occluded by PDT. Up to now,
there was no consistent and firm proof in the literature that
revascularization in the CAM after PDT involves neofor-
mation of vasculature. Several studies reported the
observed altered vascular morphology, which is compatible
with neo-angiogenesis, but proof of sprouting or vascular
proliferation was not shown [14, 23, 24]. Here we present
several lines of support for the contribution of sprouting
angiogenesis after PDT in the chorioallantoic membrane
(CAM) of the chicken embryo. We first showed that the
process of sprouting angiogenesis and the presence of
guiding tip-cells was readily observable by regular
microscopy. Secondly, we found expression of Ki-67 in the
vasculature of the PDT treated area by immunohisto-
chemistry. Thirdly, we suggest overexpression of the
endothelial angiogenesis markers aVb3-integrin, vimentin
and galectin-1, as well as suppression of the endothelial
differentiation marker ICAM-1 within the PDT treated area
at the protein level, 48 h post treatment. Fourthly, we
demonstrated pharmacological suppression of revasculari-
zation by treatment with the anti-VEGF compound Ava-
stin. Lastly, molecular profiling by quantitative real-time
RT-PCR demonstrated the spiking of the angiogenic
growth factors VEGF and bFGF as well as the upregulation
of VEGF receptors. In addition, the upregulation of the
endothelial angiogenesis markers was confirmed at the
transcriptional level.
We performed these studies in the CAM since this
model has been used for studying and optimizing the effect
of PDT on human choroidal (neo)vessels [16, 34–36]. The
CAM has been used for studying the application of PDT
for eye diseases, including exudative age-related macular
degeneration. Although the application of PDT in some
early stage cancers of the upper digestive tract, has been
very successful [37, 38], in general applications for onco-
logical diseases have been rather disappointing. Some of
these applications can be simulated in the CAM after
transplantation of tumor spheroids onto the membrane. The
Fig. 3 Representation of a PDT-treated area and a non-treated CAM
are shown in an immunohistochemical section and a fluorescence
angiography 48 h after PDT. a Histological image of the Zn-fixed
CAM, after smooth muscle actin (SMA) staining with DAB (brown)
and counterstaining with hematoxylin (purple) to visualize the nuclei.
It is indicated where PDT is applied and how the tissue morphology
changes after PDT (the PDT area is 0.02 cm2). b Part of the PDT-
treated area visualized by FITC-dextran fluorescence angiography
(25 mg/kg, 20 kDa, kex = 470 nm, kem = 520 nm) showing mor-
phologically-modified regrown vasculature in PDT-treated area as
compared to the normal non-treated vasculature
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current study provides therefore also insights and tools for
development of PDT for a number of diseases.
Our study, as well as earlier reports, supports the
hypothesis that the CAM harbors an efficient vascular
regeneration capacity similar to the human eye. After
application of PDT, new vessels are formed to replace
the original capillary plexus, a process, which is com-
pleted within 48 h (Fig. 2b and c). Larger blood vessels
were also found to be occluded, but could be recanalized
and/or reperfused. This is presumably possible because
of the fact that larger vessels are more resistant to PDT-
induced occlusion at the applied conditions. The latter
observation is consistent with results published by
Arroyo et al. [39]. However, it should be noted that we
did not quantify the number or percentage of reperfused
vessels versus newly formed vasculature in the PDT-
treated area.
The architecture of the newly formed vessels is more
tortuous and seems to be less organized when compared to
the original capillary plexus. This observation is compa-
rable to the tortuous morphology of vessels found in
angiogenic tumors, a feature that can be partially changed
by neutralization of VEGF [40], with antibody or antibody
fragment against this protein. The architecture of tubular
structures is determined by the sprouting of new tubes from
preexisting ones. The tip cells respond to a gradient of
VEGF-A by guided migration, while the proliferative
response occurs in the sprout stalk [41]. We showed by
PCR profiling that VEGF and VEGF receptors play a role
in the PDT induced angiogenesis response. Interestingly,
gene expression of both VEGF and bFGF is rapidly
induced and already measurable after 6 h, indicative of the
‘‘explosive’’ angiogenic response to the PDT induced
stress. After 24 and 48 h, the level of the angiogenic
growth factors returns to control levels, but the pro-
angiogenic condition is than maintained by enhanced
expression of the growth factor receptors.
Previous studies in the CAM model have shown that
exposure to different angiogenic stimuli, including VEGF
and bFGF, resulted in increased angiogenic activity [42,
43], and that VEGF and bFGF exibit a strong synergistic
activity [44]. Induction of VEGF expression after PDT was
also shown in several previous studies in the retinocho-
roidal area of the human eye [45, 46]. The induction of
both bFGF and VEGF after PDT (6 h post PDT) was found
by Schmidt-Erfurth et al. [27]. In this study immunohist-
opathologic examinations were performed on the eyes of
patients who underwent enucleation after PDT. Also in
oncological conditions PDT-induction of VEGF was
shown. Uehara et al. showed that tumor cells exhibit a
significantly higher VEGF expression 6 h after PDT than
those of the untreated control groups [47, 48]. It is inter-
esting to note that the kinetics and amplitude of the growth
factor responses, that we found to be both rapid and tran-
sient in origin, seem to be identical in other systems. In the
Uehara study, VEGF levels subsequently returned to con-
trol levels by 24 h after PDT. In another study by Chang
et al. [49] VEGF up-regulation following PDT was moni-
tored in the PC-3 prostate cancer model in immunodefi-
cient mice. A statistically significant increase in VEGF was
observed in PDT-treated tumors as early as 1 h post- PDT,
reaching the highest value of 2.5-fold induction as com-
pared to the control by 6 h post PDT.
Interestingly, also NRP-2, a transmembrane VEGF co-
receptor, which is predominantly expressed in vein endo-
thelial cells, in our studies also showed a rapid significant
but rather transient upregulation 6–24 h after PDT. The
other tested VEGF receptors, VEGFR-1 and VEGFR-2,
were upregulated later (24 h after PDT), and stayed high at
least up to 48 h.
Fig. 4 Immunohistochemical detection of proliferating vasculature
and expression of the angiogenesis marker aVb3-integrin in the CAM
48 h after PDT. a PDT treated CAM stained for the nuclear
proliferation marker Ki-67 (DAB, brown, arrows point to the nuclei
of proliferating cells). Arrows indicate the positive staining of nuclei
of proliferating endothelial cells. b Expression of aVb3-integrin
(brown) in a blood vessel after PDT treatment. c Negative staining for
both aVb3-integrin and Ki-67 in the normal non-treated area of the
CAM. Counterstaining with hematoxylin (purple) was performed to
visualize the nuclei. Scale bar in b applies for all panels
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The kinetics and levels of upregulation of these angio-
genic stimuli post PDT will help to provide useful infor-
mation on the optimalization of the order and timing of anti-
angiogenesis treatment when combined with PDT in order to
enhance the therapeutic effects [50]. We have recently
demonstrated improvement of PDT with ranibizumab, when
applied 24 h after PDT [14]. Based on the PCR results
obtained in the present study we expect an earlier VEGF
response, suggesting that an earlier addition may be benefi-
cial in the improvement of this combination therapy.
In order to find proof for neo-angiogenesis we also
studied the expression of markers of angiogenic
Fig. 5 Immunohistochemical
visualization of angiogenesis
regulated molecules 48 h after
PDT of the CAM. Zn-fixed and
paraffin embedded tissues were
stained with antibodies against
galectin-1 and vimentin,
markers of angiogenesis (DAB,
brown). PDT treated tissue is
more heavily stained as
compared to the normal tissue.
Tissues were also stained for
intercellular adhesion molecule
(ICAM)-1, a marker of
endothelial differentiation. For
ICAM-1, the PDT treated area is
less stained than the normal
tissue. Scale bar in lower left
panel applies for all panels
Fig. 6 Images of the CAM
vasculature before and 48 h
after PDT. Angiography images
of the CAM before (a and c) and
48 h after PDT (b and d). The
efficacy of the combination of
PDT with treatment with
Avastin, administered
topically 24 h after PDT (20 ll,
1.7 mg/ml) on the PDT-treated
area, is shown in d. Vasculature
in picture a and c is visualized
by Visudyne fluorescence
angiography (0.20 mg/kg
embryo weight, kex = 420 nm,
kem [ 470 nm). Pictures c and
d are visualized by FITC-
dextran fluorescence
angiography (25 mg/kg,
20 kDa, kex = 470 nm,
kem = 520 nm). PDT was
performed at a light dose of
20 J/cm2 and an irradiance of 60
mW/cm2. Black background
color is obtained by India ink
injection (30 ll) into the extra-
embryonic cavity right under
the treated area. Circles indicate
the PDT-treated area. Scale bar
in A applies for all panels
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endothelium. First of all, we found overexpression of
aVb3-integrin, an activation marker on endothelium [51],
in the PDT area of the CAM after 48 h. PCR analysis of the
b3 subunit of this integrin suggested confirmation of this
response. Galectin-1 and vimentin were used as other
activation markers. Galectins are a group of mammalian
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Fig. 7 Real-time RT–PCR
molecular profiling of the CAM
after PDT. Relative transcript
expression in the CAM versus
reference genes: Actin-ß and
Cyclo-A for the following
treatment groups: control
(untreated), 6 h post PDT, 24 h
post PDT, and 48 h post PDT.
a VEGF-A, b bFGF, c VEGF
receptor 1, d VEGF receptor 2,
e neuropillin-2, f integrin
b3-subunit, g galectin-1,
h vimentin. The table shows the
primer sequences used for the
molecular profiling of the CAM
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beta-galactoside binding proteins with diverse functions
that are not yet fully defined. It has been shown that
galectins have intracellular regulatory roles in RNA splic-
ing, act to inhibit or induce apoptosis, stimulate cell pro-
liferation and differentiation, and regulate the cell cycle.
Galectin-1 was previously found to function as the endo-
thelial receptor for anginex, a novel peptide angiogenesis
inhibitor [32]. In our study, galectin-1 expression was
studied. Although not exclusively expressed in the vascu-
lature, as is also the case in human and mouse tissues, we
found galectin-1 to be slightly overexpressed in the newly
formed vasculature in the PDT area as compared to the
untreated area 24 h post treatment (Fig. 5). This finding
was confirmed by PCR analysis.
Also vimentin was studied since it was reported to be
overexpressed in angiogenic endothelium [31]. We found
both at the protein and mRNA levels overexpression in the
PDT area. Interestingly, vimentin cleavage has been
reported in response to various inducers of apoptosis, such
as ionizing radiation [52] and PDT [53]. Since vimentin is
overexpressed in tumor endothelial cells [31], vimentin
cleavage may be used as a diagnostic tool to assess ther-
apeutic efficacy of PDT as well as apoptotic changes in
certain tumors treated with PDT.
Collectively, our results demonstrate that PDT induces
angiogenesis, involving among other growth factors,
VEGF and VEGF signaling. It is also shown that the
angiogenesis process resulting from Visudyne-PDT
involves both vascular neoformation, as well as reperfusion
of vessels, the former resulting in replacement of the
capillary plexus, while the latter occurs in the larger blood
vessels. The current results contribute to the possible fur-
ther improvement of PDT results by optimizing the com-
bination with angiogenesis inhibition. In particular the
possibility of further optimization of the timing of the two
therapeutic modes is indicated by the present results [54].
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